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ABSTRACT
Background and Aims Capture–recapture (CRC) analysis is recommended for estimating the prevalence of problem
drug use or people who inject drugs (PWID). We aim to demonstrate how naive application of CRC can lead to highly mis-
leading results, and to suggest how the problemsmight be overcome.Methods We present a case study of estimating the
prevalence of PWID in Bristol, UK, applying CRC to lists in contact with three services.We assess: (i) sensitivity of results to
different versions of the dominant (treatment) list: speciﬁcally, to inclusion of non-incident cases and of those who were
referred directly from one of the other services; (ii) the impact of accounting for a novel covariate, housing instability;
and (iii) consistency of CRC estimates with drug-related mortality data. We then incorporate formally the drug-related
mortality data and lower bounds for prevalence alongside the CRC into a single coherent model. Results Five of 11
models ﬁtted the full data equally well but generated widely varying prevalence estimates, from 2740 [95% conﬁdence
interval (CI) = 2670, 2840] to 6890 (95% CI = 3740, 17680). Results were highly sensitive to inclusion of non-
incident cases, demonstrating the presence of considerable heterogeneity, and were sensitive to a lesser extent to inclusion
of direct referrals. A reduced data set including only incident cases and excluding referrals could be ﬁtted by simpler
models, and led tomuch greater consistency in estimates. Accounting for housing stability improvedmodel ﬁt considerably
more than did the standard covariates of age and gender. External data provided validation of results and aided model se-
lection, generating a ﬁnal estimate of the number of PWID in Bristol in 2011 of 2770 [95% credible interval (Cr-I) = 2570,
3110] or 0.9% (95% Cr-I = 0.9, 1.0%) of the population aged 15–64 years. Conclusions Steps can be taken to reduce
bias in capture–recapture analysis, including: careful consideration of data sources, reduction of lists to less heterogeneous
subsamples, use of covariates and formal incorporation of external data.
Keywords Hidden population, People Who Inject Drugs (PWID), Bayesian analysis, Bias, Bristol, UK.
Correspondence to: Hayley E. Jones, School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK.
E-mail: hayley.jones@bristol.ac.uk
Submitted 24 June 2015; initial review completed 10 September 2015; ﬁnal version accepted 15 October 2015
INTRODUCTION
Knowledge of problem drug use prevalence and the num-
ber of people who inject drugs (PWID) is critical, serving
multiple purposes from estimating the burden of disease lo-
cally and globally, informing service planning and evaluat-
ing interventions to prevent drug-related harms [1–5].
Reliable estimates, however, are not straightforward to
obtain. Surveys seriously under-count comparatively rare,
stigmatized and vulnerable populations [6–11]. Instead,
indirect methods such as capture–recapture (CRC)
estimation have been recommended [12–15]. CRC is used
extensively to estimate the prevalence of problem drug
use [11,16–25].
The basic principle of CRC is that prevalence can be es-
timated based on the pattern of overlap between two, or
preferably more, lists of observed individuals from the tar-
get population. The number of unobserved individuals is
then estimated by ﬁtting a statistical model, usually a log-
linear regression [26], to this overlap. Added to the number
observed, this gives the total population size or prevalence.
These models are subject to assumptions which, if violated,
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can lead to invalid estimates [27–32]. Assumptions of
independence between data sources (appearing in one list
does not affect an individual’s likelihood of appearing in
another) and homogeneity of ‘capture’ probabilities (all
individuals are equally likely to appear in a list) can be re-
laxed to some extent by incorporating interaction terms
and covariates into the regression model [14,27]. However,
two key assumptions remain: (1) all variability in capture
probabilities is explained by measured covariates; and (2) in
an analysis using k lists there is no k-way dependency [14].
It has been noted that overlap between data sources may
be inﬂated by policies to refer between services (e.g. greater
integration of criminal justice and drug treatment services)
[20]. We have demonstrated that even relatively simple
referral structures can lead to violations of this second
assumption, and consequently to biased results [33]. In
particular, problems arise if the ‘saturated model’ (which
has as many parameters as there are data points) is
selected according to conventional model ﬁt criteria,
because there are many alternative such models, all of
whichhave perfect ﬁt to the observed databutwhich can pro-
duce widely differing estimates of the population size [14,33].
In this paper we show, through a case study of estimat-
ing the number of PWID in Bristol, UK, how CRC estimates
can be highly sensitive tomultiple sources of heterogeneity.
We demonstrate the need for careful selection of ‘lists’, ac-
counting for routes of referral and use of covariates. In ad-
dition, we show how the formal incorporation of other
sources of evidence related to PWID prevalence, such as
drug-related deaths, can support the generation of valid es-
timates [7,19,20,34]
METHODS
Data sources
Our PWID case deﬁnition was individuals resident in Bris-
tol aged between 15 and 64 years reporting current or pre-
vious injecting and use of opiates and/or crack cocaine
during 2011.
Cases were identiﬁed from a single database serving
multiple service providers (http://www.theseus.org.uk/)
comprising: (a) treatment in shared care with primary care
or specialist drug treatment services; (b) the Bristol Drugs
Project needle and syringe programme (NSP); and (c) the
Criminal Justice Intervention Team (CJIT), which under-
takes assessments in police custody, probation or prison.
Routine linkage of individuals between these sources is un-
dertaken by service providers based on full name (and alter-
native spellings and known aliases), date of birth and sex.
Individuals in drug treatment were categorized as ‘inci-
dent’ (a new treatment onset in 2011with at least 21 days
since last treatment discharge) or ‘non-incident’ (already
in treatment at the beginning of 2011, with no new onset
during 2011). Additionally, referrals into treatment were
categorized as ‘CJIT’ (referred directly by the CJIT) or
‘non-CJIT’ [largely general practitioner (GP), non-statutory
drug service or self-referred].
The following covariates that might inﬂuence the
‘capture’ probability (the likelihood of being observed) were
available for each of the three data sources: gender, age
group (15–24, 25–34 and 35–64 years) and instability of
housing (see Supporting information, Appendix for coding
of this variable).
External information: mortality data
We also obtained data on: (i) the number of drug-related
poisoning deaths (DRPs) that occurred in Bristol during
2011, for which opiates and/or crack cocaine were men-
tioned on the death certiﬁcate; and (ii) rates of DRP for a
large English cohort of PWID linked to the Ofﬁce for
National Statistics (ONS) mortality register [35,36]. More
details are provided in the Supporting information,
Appendix. Combined, these data can provide us with an
estimate of the number of PWID independently of the CRC.
Statistical analysis
We undertook the following analytical steps:
(i) Preliminary analysis (without covariates)
The overlap data consist of seven observed cell counts
representing the number of PWID in each combination of
the three sources. We used Poisson log-linear regression
models [26] ﬁtted in Stata version 13.1 to model these ob-
served overlaps. We ﬁtted the eight standard models usu-
ally applied in CRC estimation exercises, compared
population size estimates, and assessed model ﬁt via the
Akaike information criterion (AIC). The most complex of
these models accommodates an interaction (dependency)
between each pair of lists. This is a ‘saturated’ model,
meaning that there are as many parameters as there are
data points: it is impossible, therefore, to allow for a
three-way dependency in addition. We compared results
from three alternative saturated models in which the
three-way interaction term is included at the expense of
one of the two-way interactions [33].
(ii) The effect of referrals
We have shown previously that referrals between ser-
vice providers (e.g. directly from criminal justice into treat-
ment) can produce complex between-source dependencies,
leading potentially to misleading estimates [33]. We there-
fore re-ran all 11 regression models after excluding cases
referred via CJIT from the treatment list.
(iii) The effect of excluding non-incident cases
We hypothesized that incident treatment cases might
have different capture probabilities (i.e. a greater likelihood
of appearing in NSP or CJIT) than those treated for longer
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periods, as longer-term treatment might be associated with
a less chaotic life-style. Failure to account for this heteroge-
neity could bias results. Conversely, if heterogeneity is not
present, then estimates should be robust to exclusion of
non-incident cases. We therefore re-ran all 11 models after
restricting the treatment list to incident cases only. We per-
formed this exercise both with and without inclusion of the
CJIT referrals.
The four alternative versions of the treatment list are
shown in Box.
A Full treatment list
B CJIT referrals excluded
C All incident treatment cases
D Incident treatment cases, excluding CJIT referrals
Sensitivity of estimates to choice of treatment list was
taken as evidence of heterogeneity in the full list. Because
this violates the assumptions of CRC, we selected the least
heterogeneous treatment list to take forward into the next
stages of analysis.
(iv) Incorporation of covariates
We assumedmain effects of, and ﬁrst-order interactions
between, all three covariates. We then assessed whether
model ﬁt improved with the addition of covariate interac-
tion terms. We compared the three models which assumed
independence between data sources: (1) no covariates,
(2) all three sources depend on gender and age group
and (3) all three also depend on housing instability. There-
after, we considered extensions of the best-ﬁtting of these to
also allow for dependencies between sources.
These analyses could be performed in any standard sta-
tistical software. We used the Bayesian software WinBUGS
[37], as this facilitates the extensions in the next analytical
step. Bayesian analyses require the speciﬁcation of ‘prior’
distributions for parameters, quantifying knowledge prior
to examination of the data. We assumed vague normal
prior distributions for each regression coefﬁcient,
representing lack of prior knowledge. The results presented
are posterior medians with 95% credible intervals (Cr-Is).
Model ﬁt was compared using the Deviance information
criterion (DIC) [38], a Bayesian analogue to the AIC with
lower values implying better ﬁt, and posterior mean
residual deviance. Well-ﬁtting models should have mean
residual deviance approximately equal to the number of
data points (in this case, 84 covariate and source combina-
tions).WinBUGS code for the best-ﬁttingmodel is shown in
the Supporting information, Appendix.
(v) Incorporation of external information
Incorporation of external information alongside a CRC
analysis offers potential for model validation or formal
identiﬁcation of inconsistencies. Full details of our incorpo-
ration of external information are provided in the
Supporting information, Appendix.
Brieﬂy, we ﬁrst used DRP data in isolation to provide an
estimate of the total number of PWID independently from
the CRC. The approach used is similar to the ‘multiplier
method’ often used for prevalence estimation [8], but with
more appropriate accounting for uncertainties.
We then formally incorporated the mortality data
alongside the CRC, allowing both sources of information
to inform prevalence simultaneously [19,20], i.e. unifying
the two analyses.
Models based on reduced versions of the CRC data
(i.e. using treatment lists B–D rather than A) could pro-
duce estimates for some subpopulations that are less than
the total observed, which would be invalid. We therefore
also incorporated formally the total number of observed
PWID in each age and gender group as lower bounds.
Because the incorporation of external information has
the potential to change the optimal choice of CRC model,
we present results from each of the main competing CRC
models incorporating the external data. Our ﬁnal estimates
are from the model with the lowest DIC at this stage.
RESULTS
Characteristics of the data
The full data, stratiﬁed by all covariates and source combi-
nations, are shown in the Supporting information,
Appendix [27]. In total, 2450 PWID aged 15–64 yearswere
identiﬁed: 5% aged 15–24, 38% aged 25–35 and 57% aged
35–64 years. 73% were men and 31% were in ‘unstable’
housing; 285 were in contact with the NSP; 418 were
assessed by CJIT; and 2276 (93%) were in treatment during
2011 (full treatment list A).
Removing CJIT referrals reduced the treatment list to
2189 cases (treatment list B) and the full linked data set
to 2418. There were 674 incident treatment cases (list
C). Inclusion of only these in the treatment list reduced
the full data set to 1089. Further removing incident CJIT
referrals reduced the treatment list to 573 (list D) and the
full linked data set to 1066.
Statistical analysis
Summary results from analytical stages (i), (ii) and (iii) are
displayed in Table 1. Estimated interaction terms from each
model are displayed in the Supporting information,
Appendix.
(i) Preliminary analysis
Based on the full data set, there was clear evidence
from the AIC that at least two interaction terms were
required to explain the observed overlap. Evidence for a
positive dependence between treatment and the CJIT was
particularly strong. Five models had jointly lowest AIC
(Table 1, models 7–11). These generated widely varying
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estimates of the total number of PWID: from 2740 [95%
conﬁdence interval (CI) = 2670, 2840] to 6890 (95%
CI = 3740, 17680).
(ii) The effect of referrals
After removing CJIT referrals from the treatment list
(list B) there remained evidence for a positive dependence
between treatment and the CJIT, but the estimated size of
this was reduced considerably. The true dependence struc-
ture, however, remained unclear, the same ﬁve models still
jointly having the lowest AIC. Population size estimates
from these models were slightly less variable, but still
differed considerably (Table 1).
(iii) The effect of non-incident cases
Results were highly sensitive to inclusion of non-
incident treatment cases, providing evidence of variable
catchability, i.e. incident and non-incident treatment cases
having different probabilities of appearing in the other lists.
Inclusion of only incident cases (treatment lists C and D)
reduced the complexity of dependence structures needed
to explain the overlap and generated substantially smaller,
and more consistent, estimates.
As there was evidence of heterogeneity in the larger
treatment lists (as indicated by sensitivity of results to
removal of some cases), we selected the reduced list D to
take forward into the next stage. For this data set, the
simplest model was preferred based on the AIC, and other
models with similar AIC provided similar estimates. We
note, however, that the best-ﬁtting unadjusted (without
covariates) model gives an estimate of 2350 (95%
CI = 2140, 2600) PWID, which is below the number
observed (2450).
(iv) Incorporation of covariates
Table 2 (models 1–7) displays estimates and model ﬁt
statistics from covariate models. Corresponding gender
and age group-speciﬁc estimates are shown in Table 3.
Allowing capture probabilities to vary by gender and
age group led to some improvement in model ﬁt (11-point
reduction in DIC, relative to baseline model 1), but did not
change estimated prevalence. Gender and age group-
speciﬁc estimates were also largely robust to incorporation
of these covariates, although Cr-Is became wider.
Accounting for housing instability led to an additional
96-point reduction in the DIC, indicating substantially bet-
ter ﬁt. Incorporation of this covariate led to a slight increase
in estimated prevalence for all subgroups (Table 3, model
3) and overall (2690, 95% Cr-I = 2360, 3140).
There was evidence for a positive dependence between
treatment and the CJIT in younger males (model 5;
Table 1 Estimated size of the population of people who inject drugs (PWID) in Bristol in 2011: assessment of sensitivity of results to
exclusion of CJIT referrals and/or non-incident cases in the treatment list. Estimated interaction terms from each model are shown in the
Appendix, Supporting information.
Log-linear model Choice of treatment list (total number of PWID observed in CRC data set)
A: Full list including
CJIT referrals (2450)
B: Full list excluding
CJIT referrals (2418)
C: Incident list including
CJIT referrals (1089)
D: Incident list excluding
CJIT referrals (1066)
Estimated
population size
(95% CI)
AIC Estimated
population size
(95% CI)
AIC Estimated
population size
(95% CI)
AIC Estimated
population size
(95% CI)
AIC
(1) No
interactions
3080 (2980, 3210) 162 3330 (3190, 3500) 100 1910 (1780, 2070) 90 2350 (2140, 2600) 57
(2) T×N 2740 (2670, 2840) 93 3050 (2920, 3210) 76 1790 (1660, 1950) 84 2380 (2120, 2700) 59
(3) T×C 4000 (3670, 4420) 70 3970 (3640, 4390) 70 2490 (2180, 2890) 58 2470 (2150, 2870) 58
(4) N×C 3100 (2990, 3230) 162 3370 (3220, 3540) 97 1840 (1710, 1990) 86 2320 (2090, 2600) 59
(5) T×N + T×C 4510 (3090, 9150) 72 3750 (3080, 5120) 72 2920 (2230, 4030) 58 2770 (2210, 3620) 58
(6) T×N + N×C 2740 (2670, 2840) 95 3070 (2930, 3240) 76 1680 (1560, 1830) 76 2340 (2060, 2720) 61
(7) T×C + N×C 4260 (3850, 4790) 59 4230 (3810, 4760) 60 2490 (2110, 3010) 60 2460 (2080, 2980) 60
(8) T×N + T×C
+ N×C
6890 (3740, 17680) 59 5320 (3720, 8900) 60 3540 (2320, 5930) 59 3670 (2350, 6340) 59
(9) T×N + T×C
+ T×N×C
4510 (3090, 9150) 59 3750 (3080, 5120) 60 2920 (2230, 4030) 59 2770 (2210, 3620) 59
(10) T×N + N×C
+ T×N×C
2740 (2670, 2840) 59 3070 (2930, 3240) 60 1680 (1560, 1830) 59 2340 (2060, 2720) 59
(11) T×C + N×C
+ T×N×C
4260 (3850, 4790) 59 4230 (3810, 4760) 60 2490 (2110, 3010) 59 2460 (2080, 2980) 59
T = Treatment, N = needle exchange, C = Criminal Justice Intervention Team; e.g. ‘T×N’ refers to a treatment by needle exchange interaction term in the log-
linear model. AIC = Akaike information criterion. AIC values should be compared within columns only. Estimates from models with the lowest AIC for each
data set are shaded. CRC = capture–recapture; CJIT = Criminal Justice Intervention Team; PWID = people who inject drugs; CI = conﬁdence interval.
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six-point reduction in DIC relative to independence model)
or for a negative dependence between the NSP and CJIT for
men only (model 6; three-point reduction in DIC). These
two models gave estimates of 2960 (95% Cr-I = 2430,
3890) and 2530 (95% Cr-I = 2210, 2980), respectively.
We also ﬁtted a model in which both types of interaction
were accommodated (model 7), but this did not improve
the ﬁt further.
(v) Incorporation of external information
From the external information, we estimated the rate of
DRPs among PWID in Bristol to be 5.7 (95% Cr-I = 3.9–
8.3) per 1000 person-years. There were 15 such deaths
among PWID in Bristol in 2011. This generates an
estimate (independent of the CRC) of 2570 PWID (95%
Cr-I = 1330, 4730). Full details are provided in the
Supporting information, Appendix.
Models 3*–7* (extensions of models 3–7, respectively)
in Tables 2, 3 show prevalence estimates based on simulta-
neous modelling of the CRC, mortality data and lower
bounds. After incorporating the external data, the pre-
ferredmodel based on the DIC wasmodel 6*. Table 3 shows
thatmodel 5was in conﬂict with some of the lower bounds,
particularly for older women [predicting 170 (95%
Cr-I = 120, 250), whereas there were known to be at least
300]. The degree of conﬂict betweenmodel 6 and the lower
bounds was less, resulting in better overall ﬁt when all data
were modelled together.
Our ﬁnal estimate of the number of PWID in Bristol in
2011 was 2770 (95% Cr-I = 2570, 3110) or 0.9% (95%
Cr-I = 0.9, 1.0%) of the population aged 15–64 years.
PWID prevalence was 1.3% (95% Cr-I = 1.2, 1.5%) in
men and 0.5% (95% Cr-I = 0.5, 0.6%) in women, and
highest among men and women aged 25–34 (1.9 and
0.9%, respectively). We estimate that 89% (95%
Cr-I = 79–95%) of PWID in Bristol were in contact with
one of the three local services during 2011, and 82%
(95% Cr-I = 73–88%) were in treatment.
Our posterior estimate of the DRP rate among PWID in
Bristol, after formal incorporation with the CRC data, was
5.6 (95% Cr-I = 4.1, 7.5) per 1000 person-years. This
reﬂects some learning about mortality rates from the
CRC, in addition to learning about prevalence from the
mortality data.
DISCUSSION
We demonstrate potential biases in CRC estimation, but
show that it may be possible to: identify sublists of individ-
uals for whom application of CRC is more likely to be valid;
incorporate novel additional covariates; and use external
information to test consistency, guide model choice and
strengthen the evidence for CRC estimates.
For our case study, standard analysis of the routine data
usually used for CRC could not identify a single best
estimate: estimates from equally well-ﬁtting models varied
2.5-fold. Estimates were sensitive to inclusion of non-
incident treatment cases and deliberate referrals between
the data sources. Inclusion of such cases generates consid-
erable heterogeneity that is not accounted for by standard
methods.
Limitations
Despite the progress we have made, the estimates from our
case study should be interpreted cautiously. We found evi-
dence of heterogeneity in the full treatment list, violating a
key CRC assumption. We therefore reduced this list to a
more homogeneous subpopulation before applying CRC
techniques. However, CRC assumes that all individuals
within covariate groups (whether observed or not) have
equal capture probabilities. This means that our CRC-based
estimates relate technically only to those PWID who are
similar to those included in the reduced data set. As our
target population is, in fact, all PWID, including the
longer-term treated, we then used the total number of
observed cases to provide lower bounds. Ideally, we would
have accounted instead for heterogeneity in the full list
using observed covariates. We explored use of ‘incident’
as a covariate, but these analyses indicated a complex
between-source dependence structure among the non-
incident cases, such that it was not possible to identify a
single best-ﬁtting model. Additional factors for which we
were unable to account could also inﬂuence capture prob-
abilities [39]; for example, crack use, intensity of opiate de-
pendence, pattern of injecting and comorbidity. These were
not available from all three data sources.
We considered our target population to be people ‘at
risk’ of injecting—encompassing people with a risk of re-
lapse—which is a key quantity for policymakers and stud-
ies of injecting risk [2]. There is no accepted deﬁnition of
‘injecting risk’, with studies showing high rates of relapse
after 1 year but reducing substantially after more than
5 years [40,41]. By including all individuals who reported
ever injecting, it is conceivable that we have included some
who have ceased injecting, which would lead to an overes-
timate. Ideally we would include only individuals who had
injected in the last year, but this information was not re-
corded consistently and, even if it were, is unlikely to be
reliable.
We assumed that all matches were identiﬁed correctly,
with no misclassiﬁcation of the target population within
data sources. However, unlike many other CRC exercises,
we took lists of individuals from a single database in which
records are matched on an ongoing basis based on full de-
tails (including aliases and potential misspelling), which is
likely to minimize misclassiﬁcation errors.
There are also limitations in our external data. We as-
sume both that the 15 opiate- and crack-related deaths
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were all PWID (which is never speciﬁed on the death certif-
icate) and that the mortality rate generated from the co-
hort study is accurate (relying upon perfect matching to
ONS mortality data). It is conceivable that incorporating
other external information could reveal further biases
and alter estimates.
Implications and other evidence
Covariate CRC techniques—where heterogeneity is accom-
modated within a single model rather than by stratifying
data—have been recommended previously, but are not
adopted routinely [27,42]. National exercises in England
and Scotland [16,18] involve separate CRC estimation in
each of many subgroups. Interaction terms are then un-
likely to be statistically signiﬁcant and will be overlooked.
In addition, very few CRC studies in drug misuse have
made use of covariates other than gender and age. In our
case study, results were more sensitive to incorporation of
a variable representing instability of housing (a marker of
chaotic life-style). Similarly, Fisher and colleagues [43]
showed that mental health problems were an important
factor when estimating prevalence of homelessness. It is
important, therefore, to ensure that data sources collect
rich information regarding characteristics thatmight inﬂu-
ence ‘catchability’, to aid future prevalence estimation.
The problems around non-incident treatment cases
and referrals between services represent important poten-
tial biases to be recognized in future studies. It is our con-
tention that many recent exercises of CRC (including
potentially some of our own) may be biased, especially if
the estimates have not been validated against other data.
The data sets used for national exercises in England [18] in-
clude all treated cases (not just incident) and do not ac-
count explicitly for referrals [33]. The results are
therefore subject to the problems we have identiﬁed.
Simple ‘multiplier’ methods for estimating prevalence,
e.g. based on DRPs, are also subject to bias [4,8,44]. Tech-
niques essentially using a series or combination of multi-
pliers to minimize bias have been proposed [45,46], but
have not quantiﬁed uncertainties or formally assessed con-
sistency of evidence. Incorporation of multiple sources of
evidence in a single Bayesian analysis facilitates this, with
the potential to also allow for biased evidence [1,7,34].
Other studies have used a Bayesian approach to incorpo-
rate DRP data alongside CRC, but with weaker information
on expected mortality rates, such that the impact on prev-
alence estimates was very low, and without careful assess-
ment of heterogeneity in the CRC [19,20,47].
Our prevalence estimate of 0.9% (2770, 95%
Cr-I = 2570, 3110) conﬂicts with published estimates
[18] of PWID prevalence in England at 0.2% (0.2, 0.3%)
and in Bristol at 0.5% (1500, 95% CI = 1230, 1760) in
2011, and is towards the lower end of the conﬁdence
interval from a 2004 analysis which estimated 1.3%
(3280, 95% CI = 1940, 4610) PWID in Bristol [48]. How-
ever, our new estimate is based on drug-related mortality
data in addition to CRC, providing a stronger evidence base.
CONCLUSIONS
We would like to rescue CRC as a robust and valid method
for estimating the prevalence of problem drug use to inform
evidence-based medicine and policy making. Indirect
estimation methods are crucial, as household surveys are
not a viable alternative. However, there is a need for a step
change in the analysis, presentation and justiﬁcation of
CRC in drug misuse. Given the emerging complexity of
dependencies and heterogeneity across data sources,
researchers may need to re-focus, working with local
experts in order to understand and enrich the available
data more effectively, rather than attempting large-scale
national exercises with minimal information.
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